[S-07] Extending the clinical spectrum of cerebral amyloid angiopathy (CAA)

[S-07-2] Cerebral amyloid angiopathy-related cognitive impairment and inflammation

Kenji Sakai, Masahito Yamada (Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Sciences, Japan)

Cerebral amyloid angiopathy (CAA) , a common finding in the aging brain, is caused by accumulation of amyloid beta protein in the cerebral vasculature. Recent studies have revealed that CAA has a wider clinical spectrum than previously recognized. CAA should be in differential diagnosis of patients with lobar intracerebral hemorrhage, cognitive impairment, transient neurological symptoms, headache, and other neurological manifestations. Understanding of the growing clinical spectrum of CAA would lead to a more appropriate approach towards management of patients with CAA-related neurological disorders. In this symposium, experts in this field discuss (1) the wide clinical spectrum of CAA-related cerebrovascular disorders, (2) CAA-related cognitive impairment and inflammation, and (3) management of CAA, including current clinical implications and future perspectives for therapies against CAA.

Dr Kenji Sakai is a Neurologist and a Neuropathologist at the Department of Neurology, Kanazawa University Hospital in Kanazawa, Japan. He graduated from the Kanazawa University, Faculty of Medicine in 1999. He started his carrier as a Neuropathologist in 2002, and gained his Doctor of Philosophy degree from Kanazawa University in 2007 regarding neuropathological examination of the mouse model of DRPLA in Niigata University. He studied CAA in autopsy cases of AD after Aβ immunization in the University of Southampton between 2011 and 2013. His current research interest has focused on the pathomechanisms of CAA and widespread field of neuropathology.